Revatis S.A. • Mission, values & team • Revatis aims to be a benchmark player in cell therapy and regenerative medicine
“One of the few companies in the world with a patented technique for the collection and production of stem cells”
Didier Serteyn
Revatis has developed an innovative process to sample, isolate, differentiate and culture stem cells. These cells are characterized, available in sufficient quantity and express characteristics useful for R&D and clinical developments.
Innovation and creativity
Revatis relies on the scientific publications of a dynamic team and has a solid and evolving patent portfolio.
Vision and perspective
Revatis has a clear and reasoned approach to the potential of its technology in research and in the clinic and develops partnerships with renowned research centers and downstream companies.
Quality an security
Revatis produces stem cells in a GMP certified aseptic isolator for batch production of cells for R&D and clinical applications.
Our team
Didier Serteyn
CEO
Jean-Philippe Lejeune
Business Development
Justine Ceusters
CSO/COO
Jean-Luc Martin
CFO
Significant contribution in cell therapy and regenerative medicine
R&D programs, preclinical and clinical studies bring a new dimension in personalized veterinary and human medicine.